{"id":"https://openalex.org/W4361946591","doi":"https://doi.org/10.1158/1078-0432.c.6526571","title":"Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non\u2013Small Cell Lung Cancer","display_name":"Data from Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non\u2013Small Cell Lung Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361946591","doi":"https://doi.org/10.1158/1078-0432.c.6526571"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6526571","doi":"https://doi.org/10.1158/1078-0432.c.6526571","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526571","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6526571","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088178599","display_name":"Suresh S. Ramalingam","orcid":"https://orcid.org/0000-0002-0757-3106","observed_orcids":["https://orcid.org/0000-0002-0757-3106"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Suresh S. Ramalingam","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018835840","display_name":"Normand Blais","orcid":"https://orcid.org/0000-0003-2698-4362","observed_orcids":["https://orcid.org/0000-0003-2698-4362"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Normand Blais","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055246540","display_name":"Julien Mazi\u00e8res","orcid":"https://orcid.org/0000-0002-5921-7613","observed_orcids":["https://orcid.org/0000-0002-5921-7613"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Julien Mazieres","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046728958","display_name":"Martin Reck","orcid":"https://orcid.org/0000-0002-5348-4462","observed_orcids":["https://orcid.org/0000-0002-5348-4462"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Martin Reck","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"C. Michael Jones","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Michael Jones","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066661309","display_name":"Erzs\u00e9bet Juh\u00e1sz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erzsebet Juhasz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Laszlo Urban","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Laszlo Urban","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005875420","display_name":"Sergey Orlov","orcid":"https://orcid.org/0000-0002-3134-1989","observed_orcids":["https://orcid.org/0000-0002-3134-1989"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sergey Orlov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087836238","display_name":"Fabrice Barl\u00e9si","orcid":"https://orcid.org/0000-0001-5793-3539","observed_orcids":["https://orcid.org/0000-0001-5793-3539"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fabrice Barlesi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012648950","display_name":"Ebenezer A. Kio","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ebenezer Kio","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076236702","display_name":"Ulrich Keiholz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ulrich Keiholz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100680083","display_name":"Qin Qin","orcid":"https://orcid.org/0000-0002-6432-2944","observed_orcids":["https://orcid.org/0000-0002-6432-2944"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qin Qin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Jiang Qian","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jiang Qian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054004316","display_name":"Caroline Nickner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Caroline Nickner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074158139","display_name":"Juliann Dziubinski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Juliann Dziubinski","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100604457","display_name":"Hao Xiong","orcid":"https://orcid.org/0000-0002-7619-4740","observed_orcids":["https://orcid.org/0000-0002-7619-4740","https://orcid.org/0009-0008-8468-1750"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hao Xiong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033578335","display_name":"Peter J. Ansell","orcid":"https://orcid.org/0000-0002-4088-2840","observed_orcids":["https://orcid.org/0000-0002-4088-2840"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Ansell","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103167295","display_name":"Mark D. McKee","orcid":"https://orcid.org/0000-0003-1061-915X","observed_orcids":["https://orcid.org/0000-0003-1061-915X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark McKee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029492518","display_name":"Vincent L. Giranda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vincent Giranda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5052978985","display_name":"Vera A. Gorbunova","orcid":"https://orcid.org/0000-0001-8979-0333","observed_orcids":["https://orcid.org/0000-0001-8979-0333"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vera Gorbunova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.5907999873161316,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.5907999873161316,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.39089998602867126,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.00860000029206276,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/veliparib","display_name":"veliparib","score":0.9929999709129333},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8970000147819519},{"id":"https://openalex.org/keywords/carboplatin","display_name":"carboplatin","score":0.9079999923706055},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":1.0},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9409999847412109},{"id":"https://openalex.org/keywords/metastatic-lung-cancer","display_name":"metastatic lung cancer","score":0.8759999871253967},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9049999713897705},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.921999990940094},{"id":"https://openalex.org/keywords/lung-squamous-cell-carcinoma","display_name":"lung squamous cell carcinoma","score":0.7059999704360962},{"id":"https://openalex.org/keywords/platinum-based-chemotherapy","display_name":"platinum-based chemotherapy","score":0.5849999785423279},{"id":"https://openalex.org/keywords/dna-repair","display_name":"DNA repair","score":0.7200000286102295},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.5950000286102295},{"id":"https://openalex.org/keywords/duration-of-response","display_name":"duration of response","score":0.5490000247955322},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5680000185966492},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.5879999995231628},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.3490000069141388},{"id":"https://openalex.org/keywords/vomiting","display_name":"vomiting","score":0.503000020980835},{"id":"https://openalex.org/keywords/dyspnea","display_name":"dyspnea","score":0.3160000145435333}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.9040019512176514},{"id":"https://openalex.org/C2781312401","wikidata":"https://www.wikidata.org/wiki/Q7919041","display_name":"Veliparib","level":5,"score":0.8726617097854614},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7259185314178467},{"id":"https://openalex.org/C2779138821","wikidata":"https://www.wikidata.org/wiki/Q7118227","display_name":"PARP inhibitor","level":5,"score":0.6323695182800293},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.6065391898155212},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6003199219703674},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5934864282608032},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.556350588798523},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.4228304624557495},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.41819262504577637},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3662649393081665},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3590083122253418},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.35510849952697754},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.30109626054763794},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.11391666531562805},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.10816437005996704},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10077381134033203},{"id":"https://openalex.org/C182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","level":4,"score":0.07506391406059265},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C82381507","wikidata":"https://www.wikidata.org/wiki/Q416878","display_name":"Polymerase","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.c.6526571","doi":"https://doi.org/10.1158/1078-0432.c.6526571","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526571","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.c.6526571.v1","doi":"https://doi.org/10.1158/1078-0432.c.6526571.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526571.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6526571","doi":"https://doi.org/10.1158/1078-0432.c.6526571","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6526571","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2531125083","https://openalex.org/W2099584898","https://openalex.org/W2476451821","https://openalex.org/W3193576393","https://openalex.org/W4210797992","https://openalex.org/W2603427954","https://openalex.org/W3185723808","https://openalex.org/W2746408763","https://openalex.org/W3159120388","https://openalex.org/W1888263064"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"PARP":[2,12],"plays":[3],"an":[4],"important":[5],"role":[6],"in":[7,50,130,137,160,253],"DNA":[8],"repair.":[9],"Veliparib,":[10],"a":[11,106,250],"inhibitor,":[13],"enhances":[14],"the":[15,131,138,161,265],"efficacy":[16],"of":[17,32,40,87,108,216],"platinum":[18],"compounds":[19],"and":[20,27,44,68,97,157,163,190,233,244,248,255],"has":[21],"been":[22],"safely":[23],"combined":[24],"with":[25,54,70,91,177,242,261,268],"carboplatin":[26,43,67,92,243],"paclitaxel.":[28],"The":[29],"primary":[30],"endpoint":[31],"this":[33],"phase":[34],"II":[35],"trial":[36],"determined":[37],"whether":[38],"addition":[39],"veliparib":[41,72,132,162,201,219,269],"to":[42,66,85],"paclitaxel":[45,69,98,245],"improved":[46],"progression-free":[47],"survival":[48,153],"(PFS)":[49],"previously":[51],"untreated":[52],"patients":[53,176],"advanced/metastatic":[55],"non\u2013small":[56],"cell":[57],"lung":[58],"cancer.":[59],"Experimental":[60],"Design:":[61],"Patients":[62,260],"were":[63,114,235],"randomized":[64],"2:1":[65],"either":[71],"or":[73,78],"placebo.":[74],"Veliparib":[75,240],"(120":[76],"mg)":[77],"placebo":[79,139,164],"was":[80,127,155,206,246],"given":[81],"on":[82,102],"days":[83],"1":[84],"7":[86],"each":[88],"3-week":[89],"cycle,":[90],"(AUC":[93],"=":[94,149,173,188,198,227],"6":[95,109],"mg/mL/min)":[96],"(200":[99],"mg/m2)":[100],"administered":[101],"day":[103],"3,":[104],"for":[105],"maximum":[107],"cycles.":[110],"Results:":[111],"Overall,":[112],"158":[113],"included":[115],"(median":[116],"age,":[117],"63":[118],"years;":[119],"male":[120],"68%,":[121],"squamous":[122,178,262],"histology":[123,263],"48%).":[124],"Median":[125,151],"PFS":[126,181,254],"5.8":[128],"months":[129,136,159],"group":[133,140],"versus":[134,257],"4.2":[135],"[HR,":[141],"0.72;":[142],"95%":[143,169,184,194,223],"confidence":[144],"interval":[145],"(CI),":[146],"0.45\u20131.15;":[147],"P":[148,172,187,197,226],"0.17)].":[150],"overall":[152],"(OS)":[154],"11.7":[156],"9.1":[158],"groups,":[165],"respectively":[166],"(HR,":[167,182,192,221],"0.80;":[168],"CI,":[170,185,195,224],"0.54\u20131.18;":[171],"0.27).":[174],"In":[175],"histology,":[179],"median":[180],"0.54;":[183],"0.26\u20131.12;":[186],"0.098)":[189],"OS":[191,256],"0.73;":[193],"0.43\u20131.24;":[196],"0.24)":[199],"favored":[200,218],"treatment.":[202],"Objective":[203],"response":[204,217],"rate":[205],"similar":[207],"between":[208,237],"groups":[209],"(veliparib:":[210],"32.4%;":[211],"placebo:":[212],"32.1%),":[213],"but":[214],"duration":[215],"treatment":[220],"0.47;":[222],"0.16\u20131.42;":[225],"0.18).":[228],"Grade":[229],"III/IV":[230],"neutropenia,":[231],"thrombocytopenia,":[232],"anemia":[234],"comparable":[236],"groups.":[238],"Conclusions:":[239],"combination":[241],"well-tolerated":[247],"demonstrated":[249],"favorable":[251],"trend":[252],"chemotherapy":[258],"alone.":[259],"had":[264],"best":[266],"outcomes":[267],"combination.":[270],"Clin":[271],"Cancer":[272],"Res;":[273],"23(8);":[274],"1937\u201344.":[275],"\u00a92016":[276],"AACR.":[277]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}